# Ste UBS

## UBS (Lux) Equity Fund – China Opportunity (USD) I-A1-acc

### Data as of the end of February 2022

#### Portrait

- Very actively managed equity fund based on a concentrated equity portfolio investing in selected Chinese companies
- The manager is given great flexibility to take focused views on the most attractive stocks and exploit the best opportunities, unconstrained by the reference index.
- Diversified across sectors offering broad coverage of the Chinese market
- The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
- UBS Opportunity Equity Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Securities no.	23,319,873
ISIN	LU1017642064
Reuters symbol	-
Bloomberg Ticker	SBCEIA1 LX
Currency of account	USD
Issue/redemption	daily
Management fee p.a.	0.960%
Flat fee	1.200%
Swing pricing	yes
Benchmark	MSCI China 10/40 (net div. reinv.)

### Current data

USD	218.64
USD	332.44
USD	218.64
USD	546.85
USD	7,337.77
	reinvested
	USD USD USD

#### Key risk figures (annualised)

	2 years	3 years
Tracking error	6.88%	7.38%
Beta	0.86	0.85
Correlation	0.94	0.93
Total risk	18.02%	17.84%
Sharpe ratio	-0.22	0.14
Risk-free rate (5 years) = $1.22\%$		

The statistical ratios were calculated on the basis of logarithmic returns.

#### 10 largest positions (in %)

	Portfolio	Benchmark
TENCENT HOLDINGS LTD	9.23	7.99
KWEICHOW MOUTAI 'A' CNY1	8.99	0.97
NETEASE INC	7.98	1.78
ALIBABA GROUP HOLDING LTD	5.71	7.98
CHINA MERCHANTS BANK CNY1	5.15	1.93
Тор 5	37.06	20.65
PING AN INSURANCE 'H' CNY1	4.87	2.45
CSPC PHARMACEUTICAL GROUP LT	4.84	0.48
HONG KONG EXCHANGES & CLEAR		
HKD1	4.22	0.00
PING AN BANK CO LTD A	4.11	0.13
AIA GROUP LTD	3.19	3.19
Тор 10	58.29	26.90

Performance (in %)		
	Portfolio	Benchmark
03.2021	-6.63	-6.20
04.2021	2.23	1.28
05.2021	-1.05	1.47
06.2021	-3.30	0.30
07.2021	-13.48	-13.50
08.2021	-3.40	0.77
09.2021	-1.98	-4.64
10.2021	1.60	2.68
11.2021	-4.64	-5.37
12.2021	-1.01	-3.23
01.2022	-3.42	-5.75
02.2022	-2.38	-0.96
2022 YTD	-5.71	-6.66
2021	-25.02	-20.14
2020	29.80	30.75
2019	43.25	22.18
2018	-13.64	-18.25
2017	61.27	54.07
Ø p.a. 2 years	-3.64	1.09
Ø p.a. 3 years	3.42	1.30
since end of fund launch month		
01.2014	119.83	61.41

#### Indexed performance



Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

#### Sectors (in %) Portfolio Benchmark 17.33 **Financial services** 25.87 Telecommunication services 19.45 13.78 14.80 6.54 Consumer staples Health care 10.51 6.75 4.74 Real estate 9 5 8 9.18 Consumer discretionary 28.27 Industrials 2.17 6.41 2.16 7.02 IT Materials and supplies 4.18 1.51 0.71 Utilities 2.76 Energy 0.00 2.22 Others 4.06 0.00 Total 100.00 100.00



### UBS (Lux) Equity Fund – China Opportunity (USD) I-A1-acc

Data as of the end of February 2022

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key investor information document carefully and throughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities or other financial instruments mentioned in this document. Huns of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may make a purchase and / or sale of any of the securities or other financial instruments mentioned herein in sot intended to be construed as a solication or an orifer to buy or sell any commissions and costs charged when subscribing to and redeeming units. If whole or part of the total costs to be paids different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the details and ophnions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purpose soly. This document may not be erpodued by UBS without any guarantee or warranty and are for the recipient's personal use and information purpose. Soly, this document may not be erpodued by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may

Prospectuses, Key Investor Information (KIID), the articles of association or the investment regulations and the annual and semi-annual reports of the UBS Funds may be obtained free of charge from the management company of the Fund, the Autorité des Marchés Financiers or, as the case may be, UBS (France) SA, 69, boulevard Haussmann, 75008 Paris, and online at www.ubs.com/funds. France: This document has been published (unamended) by UBS (France) S.A., a wealth management company, a subsidiary of UBS Holding (France) SA Company with Management Board and Supervisory Board and a capital of  $\in$  132,975,556. Registered office: 69, Bd Haussmann, 75008 PARIS. tel. 01 44 56 45 45 R.C.S. Paris B 421 255 670 NAF code 64192. Approved for insurance brokerage (financial guarantee and professional indemnity insurance in accordance with articles L 512-6 and L 512-7 of the French Insurance Code). Registration number ORIAS: 07 004 822. Telephone 01.44.56.45.45 - Fax 01.44.56.45.54. www.ubs.com/france. **Spain:** CNMV registration number: 148. Representative in Spain for UBS funds established under foreign law: UBS Europe SE, sucursal en España, MARÍA DE MOLINA, 4, E-28006 MADRID. Prospectuses, key investor information (KIID), the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Europe SE, sucursal en España, MARÍA DE MOLINA Nº 4, E-28006 MADRID. AVENIDA VIENDA Nº 640, 2° A, E-08017 BARCELONA / FERNÁNDEZ Y GONZÁLEZ N° 2, PLANTA PRINCIPAL, E-41001 SEVILLA / C/ROGER DE LAURIA N° 7, 1° PLANTA, E-46002 VALENCIA / COSO N° 33, 5° A, E-50003 ZARAGOZA, CANTÓN PEQUEÑO 15, 4°, E-15003 A CORUÑA and online at www.ubs.com/funds. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/funds. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms